



Ortho RTi Announces the Issuance of 3,610,000 Shares Pursuant to its Non-Brokered Private Placement

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/

KIRKLAND, QC, May 31, 2018 /CNW/ - Ortho Regenerative Technologies Inc. (**CSE: ORTH**) ("**Ortho RTi**" or the "**Corporation**") is pleased to announce that it has issued a total of 3,610,000 Class "A" shares (the "**Shares**") pursuant to its previously announced non-brokered private placement ("**Private Placement**"). The Shares were sold at a price per share of \$0.40, for total gross proceeds to the Corporation of \$1,444,000.

The Corporation paid a cash commission of \$57,200 and issued 143,000 non-transferable share purchase warrants (the "**Finder Warrants**"). Each Finder Warrant entitles the holder thereof to acquire one Share at a purchase price of \$0.70 for a period of 18 months from the date of issuance of the Finder's Warrants.

Dr. Brent Norton, Executive Chairman and CEO of the Corporation, has subscribed for Shares pursuant to the Private Placement. The issuance of the Shares to an insider pursuant to the Private Placement will be considered a related party transaction within the meaning of Multilateral Instrument 61-101 ("MI 61-101"). The Corporation intends to rely on the exemptions from valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(1)(b) of MI 61-101 in respect of Dr. Norton's participation.

The net proceeds from the Private Placement will be used to fund research and development costs and for general corporate purposes of the Corporation.

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold in the United States except in compliance with one or more exemptions from the registration requirements of the U.S. Securities Act and applicable securities laws.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward-

looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

SOURCE Ortho Regenerative Technologies Inc.

View original content with multimedia:

<http://www.newswire.ca/en/releases/archive/May2018/31/c8046.html>

%SEDAR: 00037950E

For further information: Stephen Kilmer, Investor & Media Relations, 647.872.4849,
kilmer@orthorti.com

CO: Ortho Regenerative Technologies Inc.

CNW 16:44e 31-MAY-18